Development of the first generation c-Met kinase inhibitors: Beginning of a path to a new treatment for cancer

Molecular Cancer Therapeutics

Volumn 10, Issue 11, 2011, Pages 2022-2023

  Wang, Xueyan ^a   McMahon, Gerald ^c   Lipson, Kenneth E ^b  

^a Metabolex Inc   (United States)

^b FIBROGEN INC   (United States)

^c MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; SCATTER FACTOR RECEPTOR;

CANCER CHEMOTHERAPY; DRUG INDUSTRY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SHORT SURVEY; TUMOR GROWTH; TUMOR XENOGRAFT;

HEPATOCYTE GROWTH FACTOR; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET;

EID: 81055138734     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0714     Document Type: Short Survey

References (9)

1. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984;311: 29-33. (Pubitemid 14065275)
2. Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude G. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci U S A 1987;84:6379-83. (Pubitemid 18002806)
3. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-4. (Pubitemid 21926175)
4. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;63:7345-55. (Pubitemid 37413476)
5. Cui J, Tran-Dubé M, Shen H, Nambu M, Kung PP, Pairish M, et al. Structure based drug design of crizotinib (PF02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) and anaplastic lymphoma kinase (ALK). J Med Chem 2011;54: 6342-63.
6. Kwak EL, Bang Y-J, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
7. Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, et al. Crizotinib in ALK-rearranged Inflammatory Myofibroblastic Tumor. N Engl J Med 2010;363:1727-33.
8. Gerber DE, Minna JD. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 2010;18:548-51.
9. Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011;6:942-6.